Source: Annual Congress 2007 - Novel issues in the treatment and control of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ovcharuk, D. Fishchuk, N. Slepchenko, L. Blazhevskaya, H. Demchuk (Vinnitsya, Ukraine). Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations. Eur Respir J 2007; 30: Suppl. 51, 575

Member's Comments

No comment yet.

Related content which might interest you: Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Analysis of the causes for the frequent exacerbations and hospitalisations in patients with COPD Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Assessing the burden of repeated exacerbations among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 Factors associated with frequent exacerbations in patients with severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 369s Year: 2001 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Poor quality of life is associated with frequent exacerbations in moderate-to-severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 190s Year: 2001 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Predicting frequent exacerbations in a severe asthma centre. Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005